Elizabeth Harvey-Jones

Author

Guy's and St Thomas' NHS Foundation Trust

Also Known As

E. Harvey-Jones, Elizabeth Harvey-Jones, Elizabeth J. Harvey-Jones

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Guy's and St Thomas' NHS Foundation Trust King's College London University College London Breast Cancer Now Institute of Molecular Biology and Pathology

About

Elizabeth Harvey-Jones is an author at Guy's and St Thomas' NHS Foundation Trust specializing in medicine, t cell immunity, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	74
2	Immunology	1	1	60
3	Pharmacology	1	1	14
4	Cancer Therapeutics	1	1	14
5	Humoral Immunity	1	1	60

Elizabeth Harvey-Jones

Publications

900

Citations

H-Index

Page 1

	Year	Citations
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study Leticia Monin, Adam G. Laing, Miguel Muñoz‐Ruiz, The Lancet Oncology	2021	608
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer Thomas Powles, Naveed Sarwar, Andrew Stockdale, JAMA Oncology	2016	78
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines Leticia Monin, Adam G. Laing, Miguel Muñoz‐Ruiz, ImmunologyCancer PatientsVaccine HesitancyImmunotherapyCovid-19	2021	60
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer Elizabeth Harvey-Jones, Maya Raghunandan, Luisa Robbez‐Masson, Annals of Oncology	2024	54
Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study Jemma M. Boyle, Gemma Hegarty, Christopher Frampton, European Journal of Cancer	2021	45
The impact of national non-pharmaceutical interventions (‘lockdowns’) on the presentation of cancer patients Arnie Purushotham, Graham Roberts, Kate Haire, ecancermedicalscience	2021	41
Does Concurrent Use of CDK4/6 Inhibitors During Palliative Radiotherapy Increase Toxicity in Patients With Metastatic Breast Cancer? Sarah Howlett, Elizabeth Harvey-Jones, Daniel Smith, Clinical Oncology Metastatic Breast CancerOncologyBreast OncologyRadiation TherapyMedicine	2020	14

Page 1